In Reply to Nevens et al

To the Editor: My co-authors and I appreciate the response of Nevens et al to the publication of our article, "Single-arm phase 2 trial of elective nodal dose reduction for patients with locoregionally advanced squamous cell carcinoma of the head and neck" (1, 2). We included in our discussion their group's randomized trial of 40 Gy versus 50 Gy elective nodal irradiation (ENI), in which "concurrent chemotherapy was allowed" but not further discussed and no analysis of elective nodal failures (ENF) was performed (3).

https://ift.tt/2H2Byrk